钆滞留:儿科放射科医生应关注吗及如何与家庭沟通
本文综述钆对比剂特性,区分钆滞留、肾源性系统性纤维化及「钆沉积病」;讨论指南与儿科使用现状,提出无证据风险时不应拒绝合理适应症的GBCA,并提供与家庭沟通框架。
要点
- 钆滞留经影像和组织学证实,但无科学公认的直接临床效应。
- 需区分钆滞留、肾源性系统性纤维化及「钆沉积病」。
- 无证据风险时不应因担心滞留而拒绝合理适应症的GBCA。
诊断标准与关键数值
- 钆滞留指GBCA给药后脑及其他器官的钆沉积,经影像识别并经组织学确认。
- 肾源性系统性纤维化于2006年在严重肾衰竭患者中被发现由GBCA引起。
- 「钆沉积病」或「钆毒性」与钆滞留及肾源性系统性纤维化为不同概念。
临床应用与阅片要点
- 对有合理适应症的患儿不应因钆滞留担忧而拒绝使用GBCA。
- 与家庭沟通时需区分钆滞留、肾源性系统性纤维化和「钆沉积病」。
- 参考社会指南和当前儿科使用实践决定GBCA使用。
局限性
- 为综述性文章,未报告系统检索范围和纳入文献标准。
- 未提供钆滞留临床效应的直接证据或定量数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gadolinium retention in the brain and other organs has recently been identified by imaging and confirmed histologically. No direct clinical effects of gadolinium retention, which occurs after gadolinium-based contrast agent (GBCA) administration for MRI, have been scientifically accepted at this time. However, there is understandable concern among medical professionals and the public about the potential effects of gadolinium retention, particularly in the brain. Part of this concern might stem from the identification of nephrogenic systemic fibrosis caused by GBCAs in people with severe renal failure in 2006. This article briefly describes the characteristics of GBCAs; reviews and differentiates gadolinium retention, nephrogenic systemic fibrosis, and "gadolinium deposition disease" or "gadolinium toxicity"; and discusses societal guidelines and current usage in children. With the belief that GBCAs should not be withheld for appropriate indications in the absence of evidence of its potential risks, we offer a framework for determining when GBCA use is appropriate and suggestions for discussing its risks and benefits with children and their families.
引用
- Noda SM, Oztek MA, Stanescu AL, et al. Gadolinium retention: should pediatric radiologists be concerned, and how to frame conversations with families. Pediatr Radiol. 2021. PMID: 33978802. doi:10.1007/s00247-021-04973-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。